SCM
Superstring Capital Management Portfolio holdings
AUM
$80.3M
This Quarter Return
+14.15%
1 Year Return
+68.23%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$80.3M
AUM Growth
+$80.3M
(-4.3%)
Cap. Flow
-$14.2M
Cap. Flow
% of AUM
-17.64%
Top 10 Holdings %
Top 10 Hldgs %
61.84%
Holding
47
New
13
Increased
9
Reduced
9
Closed
11
Top Buys
| 1 |
Neurocrine Biosciences
NBIX
|
$5.1M |
| 2 |
Ultragenyx Pharmaceutical
RARE
|
$4.74M |
| 3 |
Jazz Pharmaceuticals
JAZZ
|
$4.68M |
| 4 |
Ionis Pharmaceuticals
IONS
|
$3.88M |
| 5 |
BCAX
Bicara Therapeutics Inc. Common Stock
BCAX
|
$1.76M |
Top Sells
| 1 |
Zai Lab
ZLAB
|
$5.6M |
| 2 |
Legend Biotech
LEGN
|
$5.44M |
| 3 |
Pfizer
PFE
|
$4.97M |
| 4 |
Oric Pharmaceuticals
ORIC
|
$4.81M |
| 5 |
UroGen Pharma
URGN
|
$4.6M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
MoonLake Immunotherapeutics
MLTX
$3.72B
| $832K | 0.98% |
17,623
-14,522
| -45% | -$685K |
|
27
Ocular Therapeutix
OCUL
$2.21B
| $826K | 0.98% |
88,980
+46,683
| +110% | +$433K |
|
28
Rocket Pharmaceuticals
RCKT
$350M
| $525K | 0.62% |
+214,412
| New | +$525K |
|
29
Wave Life Sciences
WVE
$1.53B
| $457K | 0.54% |
+70,242
| New | +$457K |
|
30
Biomea Fusion
BMEA
$121M
| $450K | 0.53% |
+250,000
| New | +$450K |
|
31
Kyverna Therapeutics
KYTX
$155M
| $438K | 0.52% |
142,542
-48,745
| -25% | -$150K |
|
32
Century Therapeutics
IPSC
$41.1M
| $259K | 0.31% |
462,963
| – | – |
|
|
SY
33
So-Young International
SY
$376M
| $226K | 0.27% |
+72,936
| New | +$226K |
|
34
RAPT Therapeutics
RAPT
$196M
| $208K | 0.25% |
+26,034
| New | +$208K |
|
|
LSB
35
LakeShore Biopharma
LSB
$33.9M
| $31.4K | 0.04% |
30,792
| – | – |
|
36
Capricor Therapeutics
CAPR
$289M
| – | – |
-241,192
| Closed | -$2.29M |
|
37
Cumberland Pharmaceuticals
CPIX
$55.2M
| – | – |
0
| – | – |
|
38
Crinetics Pharmaceuticals
CRNX
$3.14B
| – | – |
-43,613
| Closed | -$1.46M |
|
|
39
Legend Biotech
LEGN
$6.32B
| – | – |
-160,442
| Closed | -$5.44M |
|
40
Madrigal Pharmaceuticals
MDGL
$9.72B
| – | – |
-3,815
| Closed | -$1.26M |
|
41
Vaxcyte
PCVX
$4.1B
| – | – |
-11,264
| Closed | -$425K |
|
|
42
Pfizer
PFE
$142B
| – | – |
-196,164
| Closed | -$4.97M |
|
43
Schrodinger
SDGR
$1.41B
| – | – |
-14,114
| Closed | -$279K |
|
44
Summit Therapeutics
SMMT
$17.7B
| – | – |
-132,019
| Closed | -$2.55M |
|
|
SWTX
45
DELISTED
SpringWorks Therapeutics
SWTX
| – | – |
-54,216
| Closed | -$2.39M |
|
46
Taysha Gene Therapies
TSHA
$775M
| – | – |
-755,599
| Closed | -$1.05M |
|
47
Verastem
VSTM
$567M
| – | – |
-336,363
| Closed | -$2.03M |
|